Bioanalytical Strategy Lead
AstraZeneca
Indi is a Bioanalytical Strategy Lead at AstraZeneca with expertise in pharmacokinetics (PK) and anti-drug antibody (ADA) assays. In her current role, she provides strategic oversight for both pre-clinical and clinical bioanalytical strategies, driving the development and validation of assays that support a diverse portfolio of emerging therapeutic modalities including T-cell engagers, bispecific antibodies, and antibody-drug conjugates. Indi earned her PhD in biochemistry from Michigan State University and completed her postdoctoral training at the University of Pennsylvania. She is an active member of multiple industry working groups, contributing to the advancement of bioanalytical strategies across the field.
Disclosure information not submitted.
Beyond the Analysis: Pre-Analytics and Logistics
Tuesday, July 15, 2025
1:30 PM - 3:00 PM ET
Tuesday, July 15, 2025
2:50 PM - 3:00 PM ET